{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:00:07Z","timestamp":1791212407864,"version":"4.1.0"},"reference-count":117,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T00:00:00Z","timestamp":1455062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunological Reviews"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Bispecific T\u2010cell engager (Bi<jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content><jats:sup>\u00ae<\/jats:sup>) antibody constructs represent a novel immunotherapy that bridges cytotoxic T cells to tumor cells, thereby inducing target cell\u2010dependent polyclonal T\u2010cell activation and proliferation, and leading to apoptosis of bound tumor cells. Anti\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>19 Bi<jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content><jats:sup>\u00ae<\/jats:sup> blinatumomab has demonstrated clinical activity in Philadelphia chromosome (Ph)\u2010negative relapsed or refractory (r\/r) acute lymphoblastic leukemia (<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>) eventually resulting in conditional approval by the U.S. Food and Drug Administration in 2014. This drug is currently further developed in pediatric and Ph<jats:sup>+<\/jats:sup> r\/r, as well as in minimal residual disease\u2010positive <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>, and might also offer clinical benefit for patients with non\u2010Hodgkin's lymphoma, especially for those with aggressive forms like diffuse large B\u2010cell lymphoma. Another Bi<jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content><jats:sup>\u00ae<\/jats:sup> antibody construct in hemato\u2010oncology designated <jats:styled-content style=\"fixed-case\">AMG<\/jats:styled-content> 330 targets <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>33 on acute myeloid leukemia blast cells. After showing promising <jats:italic>ex\u00a0vivo<\/jats:italic> activity, this drug candidate has recently entered phase 1 clinical development, and has further indicated potential for combination with checkpoint inhibitors. In solid tumor indications, three Bi<jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content><jats:sup>\u00ae<\/jats:sup> antibody constructs have been tested in phase 1 studies so far: anti\u2010Ep<jats:styled-content style=\"fixed-case\">CAM<\/jats:styled-content> Bi<jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content><jats:sup>\u00ae<\/jats:sup> <jats:styled-content style=\"fixed-case\">AMG<\/jats:styled-content> 110, anti\u2010<jats:styled-content style=\"fixed-case\">CEA<\/jats:styled-content> Bi<jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content><jats:sup>\u00ae<\/jats:sup> <jats:styled-content style=\"fixed-case\">MEDI<\/jats:styled-content>\u2010565\/<jats:styled-content style=\"fixed-case\">AMG<\/jats:styled-content> 211, and anti\u2010<jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content> Bi<jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content><jats:sup>\u00ae<\/jats:sup> <jats:styled-content style=\"fixed-case\">BAY<\/jats:styled-content>2010112\/<jats:styled-content style=\"fixed-case\">AMG<\/jats:styled-content> 212. Pertinent questions comprise how to maximize Bi<jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content><jats:sup>\u00ae<\/jats:sup> penetration and T\u2010cell infiltration of the tumor while simultaneously minimizing any adverse events, which is currently explored by a continuous intravenous infusion approach. Thus, Bi<jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content><jats:sup>\u00ae<\/jats:sup> antibody constructs will hopefully provide new treatment options for patients in several indications with high unmet medical need.<\/jats:p>","DOI":"10.1111\/imr.12393","type":"journal-article","created":{"date-parts":[[2016,2,11]],"date-time":"2016-02-11T19:06:52Z","timestamp":1455217612000},"page":"193-208","source":"Crossref","is-referenced-by-count":152,"title":["Harnessing T cells to fight cancer with BiTE<sup>\u00ae<\/sup> antibody constructs \u2013 past developments and future directions"],"prefix":"10.1111","volume":"270","author":[{"given":"Matthias","family":"Klinger","sequence":"first","affiliation":[{"name":"Amgen Research (Munich) GmbH Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Benjamin","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Kischel","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Stienen","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Zugmaier","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,2,10]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2014.01.004"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2703"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-2458"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.04.001"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1016700"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015586218"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500751"},{"key":"e_1_2_9_12_1","article-title":"Anti\u2010CD19 chimeric antigen receptor\u2010modified T cells for B\u2010cell malignancies: a systematic review of efficacy and safety in clinical trials","author":"Zhu Y","year":"2015","journal-title":"Eur J Haematol"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1041373"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/314628a0"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2011.03.010"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.03.007"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2008.11.014"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.08.025"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.6.2098"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.07.034"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318156750c"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10557"},{"key":"e_1_2_9_23_1","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.4049\/jimmunol.158.8.3965","article-title":"Biologic properties of a bispecific single\u2010chain antibody directed against 17\u20101A (EpCAM) and CD3: tumor cell\u2010dependent T cell stimulation and cytotoxic activity","volume":"158","author":"Mack M","year":"1997","journal-title":"J Immunol"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0956"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0298-z"},{"key":"e_1_2_9_26_1","first-page":"3252","article-title":"Effector memory T cells make a major contribution to redirected target cell lysis by T cell\u2010engaging BiTE antibody MT110","volume":"69","author":"Kischel R","year":"2009","journal-title":"Cancer Res"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-014-9529-x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2012-4841"},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood.V124.21.2291.2291","article-title":"Crucial role of regulatory T cells in predicting the outcome of the T cell engaging antibody blinatumomab in relapsed and refractory B precursor ALL patients","volume":"124","author":"Duell J","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20908"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.559668"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402890"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.8.4397"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-005-0001-1"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.07.013"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.3051"},{"key":"e_1_2_9_37_1","doi-asserted-by":"crossref","first-page":"7020","DOI":"10.1200\/jco.2013.31.15_suppl.7020","article-title":"Immunopharmacodynamic response to blinatumomab in patients with relapsed\/refractory B\u2010precursor acute lymphoblastic leukemia (ALL)","volume":"31","author":"Schub A","year":"2013","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.64"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-400515"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7270"},{"key":"e_1_2_9_42_1","volume-title":"Acute Lymphoblastic Leukemia: Epidemiology and Etiology","author":"Wartenberg D","year":"2008"},{"key":"e_1_2_9_43_1","volume-title":"SEER Cancer Statistics Review, 1975\u20102012","author":"Howlader N"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.1382"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.8018"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-164863"},{"key":"e_1_2_9_47_1","volume-title":"Management of Ph\u2013 ALL Relapse\/New Drugs in Ph\u2013 ALL","author":"Dombret H","year":"2011"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25354"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.2309"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377713"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-441030"},{"key":"e_1_2_9_53_1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood.V124.21.379.379","article-title":"BLAST: a confirmatory, single\u2010arm, phase 2 study of blinatumomab, a bispecific T\u2010cell engager (BiTE\u00ae) antibody construct, in patients with minimal residual disease B\u2010precursor acute lymphoblastic leukemia (ALL)","volume":"124","author":"Goekbuget N","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.239"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.100073"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.4.1188.bloodjournal8841188"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.4403"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"},{"key":"e_1_2_9_61_1","first-page":"151","article-title":"Final results from a phase 1 study of blinatumomab in patients with relapsed\/refractory non\u2010Hodgkin's lymphoma","volume":"31","author":"Goebeler ME","year":"2013","journal-title":"Hematol Oncol"},{"key":"e_1_2_9_62_1","first-page":"181","article-title":"Blinatumomab treatment in relapsed\/refractory diffuse large B\u2010cell lymphoma in an open\u2010label, phase 2 study: safety, efficacy and late responses","volume":"33","author":"Viardot A","year":"2015","journal-title":"Hematol Oncol"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.389"},{"key":"e_1_2_9_64_1","first-page":"575","article-title":"The role of myeloablation for lymphoma","volume":"370","author":"Stiff PJ","year":"2014","journal-title":"N Engl J Med"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1399"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9277"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf256"},{"key":"e_1_2_9_70_1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V124.21.391.391","article-title":"Positron emission tomography (PET) guided therapy of aggressive lymphomas \u2013 a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL trial)","volume":"124","author":"Duehrsen U","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_9_72_1","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood.V124.21.630.630","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B\u2010cell lymphoma: the Orcharrd study (OMB110928)","volume":"124","author":"Imhoff GW","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12846"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.291.291"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-13150-4_8"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2216"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-154013"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70106-3"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635169"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-260117"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.8.2005.bloodjournal8582005"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-440X(02)00375-5"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.169.5.1721"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwj008"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2014.04.001"},{"key":"e_1_2_9_86_1","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood.V68.5.1030.1030","article-title":"The L4F3 antigen is expressed by unipotent and multipotent colony\u2010forming cells but not by their precursors","volume":"68","author":"Andrews RG","year":"1986","journal-title":"Blood"},{"key":"e_1_2_9_87_1","first-page":"442","article-title":"Effects of anti\u2010CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in\u00a0vitro hematopoiesis in long\u2010term marrow cultures","volume":"20","author":"Russa VF","year":"1992","journal-title":"Exp Hematol"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0205096"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1309\/1WMW-CMXX-4WN4-T55U"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-523548"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/35102167"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1072"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-325050"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-466706"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60485-1"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527044"},{"key":"e_1_2_9_97_1","article-title":"Blockade of the PD\u20101\/PD\u2010L1 axis augments lysis of AML cells by the CD33\/CD3\u2010BiTE(R) antibody construct AMG 330: reversing a T\u2010cell induced immune escape mechanism","author":"Krupka C","year":"2015","journal-title":"Leukemia"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0189-2"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001099900038"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03312-2"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:BREA.0000036787.59816.01"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0754"},{"key":"e_1_2_9_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.03.035"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1824"},{"key":"e_1_2_9_105_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0654"},{"key":"e_1_2_9_106_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181a1c097"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0529-y"},{"key":"e_1_2_9_108_1","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1200\/jco.2012.30.15_suppl.2504","article-title":"A phase I study of EpCAM\/CD3\u2010bispecific antibody (MT110) in patients with advanced solid tumors","volume":"30","author":"Fiedler WM","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605364"},{"key":"e_1_2_9_110_1","first-page":"85","article-title":"In vitro MABEL approach for nonclinical safety assessment of MEDI\u2010565 (MT111)","volume":"1","author":"Ryan PC","year":"2012","journal-title":"ALTEX Proc"},{"key":"e_1_2_9_111_1","doi-asserted-by":"crossref","first-page":"TPS3097","DOI":"10.1200\/jco.2015.33.15_suppl.tps3097","article-title":"Phase I study of AMG 211\/MEDI\u2010565 administered as continuous intravenous infusion for relapsed\/refractory gastrointestinal (GI) adenocarcinoma","volume":"33","author":"De Vries E","year":"2015","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_112_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31819b7c70"},{"key":"e_1_2_9_113_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.1.14193"},{"key":"e_1_2_9_114_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0042"},{"key":"e_1_2_9_115_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1671-y"},{"key":"e_1_2_9_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(14)70661-6"},{"key":"e_1_2_9_117_1","doi-asserted-by":"publisher","DOI":"10.4161\/19420862.2014.975660"},{"key":"e_1_2_9_118_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1000976107"}],"container-title":["Immunological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimr.12393","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimr.12393","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imr.12393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T11:57:02Z","timestamp":1694519822000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imr.12393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,10]]},"references-count":117,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1111\/imr.12393"],"URL":"https:\/\/doi.org\/10.1111\/imr.12393","archive":["Portico"],"relation":{},"ISSN":["0105-2896","1600-065X"],"issn-type":[{"value":"0105-2896","type":"print"},{"value":"1600-065X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,10]]}}}